Przedstawiamy wybór publikacji naukowych związanych z immunoterapią IOZK. Możesz użyć filtrów, aby dokonać wyboru według typów nowotworów i metod lub wprowadzić wyszukiwane hasła.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-12-06 / Gynecol. Oncol. 2009 Feb;112(2):384-8https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-12-06 / Gynecol. Oncol. 2009 Feb;112(2):384-82008-12-06 00:00:002008-12-06 00:00:00Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – a phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-12-04 / Lung Cancer 2009 Jul;65(1):1-8https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-12-04 / Lung Cancer 2009 Jul;65(1):1-82008-12-04 00:00:002019-02-15 08:34:57Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-12-01 / Int J Hyperthermia 2008 Dec;24(8):649-62https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-12-01 / Int J Hyperthermia 2008 Dec;24(8):649-622008-12-01 00:00:002019-02-15 09:17:39Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-28 / Cancer Lett. 2008 Nov;271(2):333-41https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-28 / Cancer Lett. 2008 Nov;271(2):333-412008-11-28 00:00:002019-02-15 09:16:51Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-41https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-412008-11-27 00:00:002019-02-15 09:19:13Dendritic cells in the skin–potential use for melanoma treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-80https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-802008-11-16 00:00:002019-02-15 08:44:32Recent advances in cancer vaccines: an overview
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-15 / Cancer Res. 2008 Nov;68(22):9441-50https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-502008-11-15 00:00:002019-02-15 09:19:16Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-9002008-11-08 00:00:002021-11-15 17:03:25Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-8https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-82008-11-01 00:00:002019-02-15 09:19:15[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-403https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-4032008-10-23 00:00:002019-02-15 09:19:13The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
Immunotherapy in acute leukemia
New therapeutic strategies in acute lymphoblastic leukemia
The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis
Mechanisms of murine dendritic cell antitumor dysfunction in aging
Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – a phase II study
Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol
Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice
Dendritic cells in the skin–potential use for melanoma treatment
Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection
Recent advances in cancer vaccines: an overview
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients
Dendritic cell vaccines for the treatment of prostate cancer
[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo
The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma